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ABSTRACT
Currently, traditional and non- traditional risk factors 
for cardiovascular disease have been established. The 
first group includes age, which constitutes one of the 
most important factors in the development of chronic 
diseases. The second group includes inflammation, the 
pathophysiology of which contributes to an accelerated 
process of vascular remodelling and atherogenesis in 
autoimmune diseases. Indeed, the term inflammaging 
has been used to refer to the inflammatory origin of 
ageing, explicitly due to the chronic inflammatory process 
associated with age (in healthy individuals). Taking this into 
account, it can be inferred that people with autoimmune 
diseases are likely to have an early acceleration of 
vascular ageing (vascular stiffness) as evidenced in 
the alteration of non- invasive cardiovascular tests such 
as pulse wave velocity. Thus, an association is created 
between autoimmunity and high morbidity and mortality 
rates caused by cardiovascular disease in this population 
group. The beneficial impact of the treatments for 
rheumatoid arthritis at the cardiovascular level has been 
reported, opening new opportunities for pharmacotherapy.
BACKGROUND
Age is the strongest independent risk factor 
for the onset and progression of many of 
the major non- congenital chronic diseases 
including cancer, neurodegenerative diseases 
and cardiovascular diseases (CVDs).1 It has 
been proposed that these chronic diseases 
are manifestations of an accelerated ageing 
process.1 With the recent advance in the 
understanding of the molecular mechanisms 
of ageing, an interest in biomarkers capable 
of differentiating between biological and 
chronological age has developed, because 
such biomarkers might improve risk predic-
tion for this group of diseases.1–5 Exploration 
of the molecular mechanisms has generated 
the following list of factors that cause ageing: 
defective repair of DNA damage, imbalance 
in the production and elimination of cellular 
debris, defective self- molecules that can be 
recognised by the innate immune system 
and induce ‘inflammaging’, mitochondrial 
dysfunction, and cellular senescence.6
At the vascular level, ageing gradually 
affects the structure and function of blood 
vessels, thus causing loss of elasticity of the 
arterial wall and endothelial dysfunction.2 3 7 
As the world population ages, establishing the 
physiological connection between these 
features of vascular ageing and the causal 
molecular mechanisms of ageing is of great 
value for the prevention of vascular disease.4 
In this review, we focus on inflammaging, 
which is importantly connected with the 
impact of autoimmune diseases (AIDs) and 
treatment thereof on the cardiovascular 
system. We first discuss the theoretical back-
ground of this connection, then explore the 
Key messages
What is already known about this subject?
 ► ‘Inflammaging’ is characterised by the presence of 
persistent low- grade inflammation that develops 
with age and causes deficient tissue repair and de-
generation, and it is reflected as an increase in the 
plasma levels of inflammatory cytokines and acute- 
phase reactants.
What does this study add?
 ► The low- grade, persistent pro- inflammatory milieu 
characteristic for the ageing process triggers mor-
phological and functional changes, most prominent-
ly endothelial dysfunction, diffuse intimal–medial 
thickening and arterial stiffness.
How might this impact on clinical practice?
 ► The pattern of cytokine expression observed in 
autoimmune diseases, like rheumatoid arthritis, is 
similar to that seen in ‘inflammaging’ with similar 
consequences as increase vascular ageing induced 
by this chronic inflammation.
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epidemiological relationship between AID and vascular 
ageing as a read- out of this connection, and, finally, 
discuss the options for pharmacotherapy.
Inflammatory origin of ageing ‘inflammaging’ and AIDs
In the year 2000, Franceschi et al introduced the term 
‘inflammaging’ (inflammation+ageing) to describe the 
chronic, sterile, low- grade inflammatory process that 
develops with age, confers susceptibility to suffering 
age- related pathologies and facilitates the spread of the 
effects of ageing at the systemic level.1 8 9 ‘Inflammaging’ is 
considered to be caused by endogenous signals resulting 
from an imbalance between the production and disposal 
of cellular debris and defective self- molecules. Thus, 
‘inflammaging’ could be defined as a process of autoim-
mune/self- reactive origin.1 5 This new theory establishes 
inflammation as a fundamental component for the phys-
iology of ageing and its associated diseases.1 5
The increase in inflammaging is related to immune 
senescence, the complex remodelling process the 
immune system undergoes with ageing.9 10 In the adaptive 
immune system, this remodelling process is characterised 
by thymic involution, a reduced number of naïve T cells, 
a relative increase in memory T cells, and the reduction 
of antibodies diversity and affinity. Thymic involution is 
associated with the release of autoreactive T cells that 
recognise endogenous molecules and contribute to the 
inflammaging.11 The changes in the innate immune 
system are less clear, but it has been reported that 
macrophages and dendritic cells become less respon-
sive to antigens of the innate immune system during 
ageing8 12 (figure 1). In the circulation, the inflammaging 
is reflected as altered levels of pro- inflammatory cytokines 
(interleukin 6 (IL-6), IL-1β, IL-8, tumour necrosis factor 
alpha (TNF-α), interferon gamma (IFN-γ)), acute- phase 
reactants (C reactive protein (CRP)), and decreases in 
IL-10 and IL-1 receptor antagonist (IL- 1RA).5
Even in long- lived healthy individuals, ageing occurs 
secondary to a state of low- grade, chronic subclinical 
inflammation.13 However, conditions presenting with 
a high inflammatory burden will favour or accelerate 
the ageing process. Such is the case of AID, where the 
dysregulation in innate and adaptive immune systems 
Figure 1 Remodelling of the immune system with ageing. Disturbances in the immunological system are associated with a 
dysregulation in both the innate and adaptive immune system. Also, the exposome as a cumulative measure of external stimuli 
and the biological responses throughout the lifespan associated with the genetic background play an important role in the 
response of the immunological system.
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stimulates autoantibody production and a chronic 
immune- mediated inflammatory response. This chronic 
inflammatory process affects different organs and systems 
including the cardiovascular system.14 15 It has been shown 
that people with AID present high rates of morbidity and 
mortality from cardiovascular events.16 17 This is associ-
ated with an accelerated degree of arteriosclerosis and 
remodelling of the blood vessels.14 Arteriosclerosis is a 
descriptive broad term for the thickening and hardening 
of the arterial wall. One important cause of arterioscle-
rosis is atherosclerosis, which is a patchy abnormality in 
the artery wall frequently associated with ageing, lipid 
deposits and activation of inflammatory pathways.
Therefore, both the elderly and patients with AID 
present remodelling of the immune system and chronic 
inflammation, low- grade in healthy long- lived individ-
uals, that is, in normal ageing, or more severe in patients 
with AID, that is, in accelerated ageing. Moreover, there 
are similarities in the pattern of cytokine expression 
observed in AID and that seen in ‘inflammaging’ with 
similar effects in the arterial remodelling process as will 
be discussed later.15
CVD and autoimmunity
AID and cardiovascular risk
CVD is the main cause of morbidity and mortality world-
wide, and its incidence has risen by around one- third in 
the last decade.18 Among the pathophysiological mech-
anisms of arteriosclerotic CVD, a chronic inflammatory 
process sustained by a progressive imbalance in the 
production of pro- inflammatory and anti- inflammatory 
molecules with age plays a pivotal role. In patients with 
AID, this chronic inflammatory state starts from early life, 
explaining the high premature cardiovascular morbidity 
and mortality.19 20
Indeed, the risk of cardiovascular events and death 
in patients with rheumatoid arthritis (RA) and other 
inflammatory arthropathies (ankylosing spondylitis and 
psoriatic arthritis) is substantially high compared with 
the general population. This risk is comparable with 
that in patients with diabetes mellitus, which, like AID, is 
featured by a chronic pro- inflammatory status. Diabetes 
mellitus is one of the most important cardiovascular risk 
factors as shown in studies such as the ‘CARRÉ Investiga-
tion’ where it was evidenced that the prevalence of CVD 
was 5.0% (95% CI 2.3% to 7.7%) in the group without 
diabetes, 12.4% (95% CI 7.5% to 17.3%) in the group 
with diabetes mellitus type 2 (DM2) and 12.9% (95% CI 
8.8% to 17.0%) in those with RA.21 In RA, the prevalence 
of CVD ranges from 12% to 67.6% and is considered 
to be one of the most frequent extra- articular mani-
festations22; while in controls, this prevalence ranges 
from 10% to 30%.23 This prevalence varies according 
to study design, the specific definition of CVD and of 
composite outcomes (ie, including or not arterial hyper-
tension, stroke, ischaemic heart diseases and so on), the 
relationship to disease duration (early or established 
RA) and cardiovascular risk factors (ie, traditional or 
non- traditional), and inclusion of RA treatment. In addi-
tion, there is an increased risk of presenting with acute 
coronary syndrome, worse short- term outcomes and 
increased circulatory system diseases mortality (32%) in 
patients with RA.24 In fact, a meta- analysis25 found that 
the risk of incident CVD is increased by 48% in patients 
with RA compared with the general population. In the 
case of systemic lupus erythematosus (SLE), an AID 
that affects multiple organs, sometimes from young age 
on, cardiovascular risk is elevated four to eight times 
compared with the normal population. This has been 
shown in some cohorts with a higher absolute CVD risk 
(23% SLE vs 7% controls; HR 3.8, 95% CI 1.8 to 8) and 
an estimated 10- year mortality rates of 26% for subjects 
with SLE vs 19% for comparisons.26 27
Common inflammatory processes in AID and CVD
The relationship between AID and the development of 
CVD is shaped both by the presence of traditional cardi-
ovascular risk factors (dyslipidaemia, smoking, metabolic 
syndrome and so on) as well as by non- traditional risk 
factors such as chronic inflammation, components of 
the innate and adaptive immune system, subphenotypes 
of clinical severity, genetic factors associated or not with 
human leucocyte antigen (ie, TNF super family genes, 
cytokines and related genes, chemokines, adipokines 
and nitric oxide synthase genes, among others),20 and 
the additive protective or adverse effect of some cardio-
vascular and anti- inflammatory medications used.14 19 In 
patients with AID, the presence of underlying microvas-
cular and macrovascular lesions, and the production of 
inflammatory mediators in the perivascular layers have 
been described. This includes accumulation of lipid parti-
cles, autoantibodies, autoantigens, and the production 
of multiple inflammatory cytokines such as TNF-α and 
inflammatory cell infiltrates, consisting mainly of lympho-
cytes in the outer vascular and perivascular layers.14 There 
is increasing evidence supporting the direct proportional 
relationship between the inflammatory burden of the 
underlying disease and the risk of adverse cardiovascular 
outcomes.28 In the RA case, functional abnormalities 
of the endothelium and carotid plaque formation have 
been found associated with duration of disease, degree 
of disease activity, rheumatoid factor seropositivity and 
elevated markers of systemic inflammation. On the other 
hand, in SLE, some factors associated with overt CVD 
were found more often in SLE cases than controls: lupus 
anticoagulant, higher cumulative dosage of steroids, 
high alpha-1 antitrypsin, inflammatory markers (eg, CRP, 
fibrinogen, IL-6), adhesion molecules and immunolog-
ical factors (eg, anticardiolipin antibodies, anti- beta II 
glycoprotein antibodies, antibodies against oxidised low- 
density lipoproteins (LDLs) and anti- heat shock protein 
antibodies).28 Furthermore, some studies have shown 
that the duration of the disease increases this risk, prob-
ably due to prolonged exposure to inflammation.29
In this same context, the exaggerated production 
of molecules such as CRP, fibrinogen and cytokines in 
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patients with AID implies a chronic pro- inflammatory 
environment that favours endothelial dysfunction and 
vascular remodelling, and induces other cardiovascular 
risk factors such as an increased production of lipids 
(low- density oxidised lipoprotein). These act as a pro- 
inflammatory stimulus in association with CRP, by forming 
pro- atherogenic complexes, activating endothelial cells, 
regulating the production of adhesion molecules and 
the secretion of chemokines that recruit monocytes or 
macrophages, and magnifying and perpetuating this 
process.29 30 Moreover, pro- inflammatory molecules 
are involved in plaque instability. IFN-γ, a key mole-
cule involved in the rupture of atheromatous plaques, 
is also upregulated in the inflammation associated with 
AID.31 32 Upregulation of this molecule in T lymphocytes 
located at the plaque inhibits the production of extra-
cellular components (mainly collagen) by the muscle 
cells, contributing to the thinning of the fibrous cap.31 32 
Additionally, activated T lymphocytes express CD40L, 
a molecule that induces foam cells into the production 
of collagenases and gelatinases that degrade the extra-
cellular matrix. Finally, the thinning of the fibrous cap 
predisposes to plaque rupture, thrombosis and occlusion 
of the lumen, a key process in the development of acute 
CVDs.31
Components of the ‘inflammaging’: common role of pro-
inflammatory molecules in AID
Pro- inflammatory cytokines have been identified as a 
fundamental component of ‘inflammaging’ since they 
can encourage the expansion of clones of the haemato-
poietic/immune system depending on the spread of 
inflammatory signals. In the bone marrow, the immune 
system of senile individuals is progressively dominated by 
T and B cell clones, which probably represent an adap-
tation of the senescent immune system. In fact, these 
T/B clones represent the result of chronic exposure to 
antigens that can encompass chronic latent infections, 
microbiota and autoantigens. The latter can arise de 
novo during ageing as a self- recognition disorder. Clones 
of the expanded immune/haematopoietic system are 
likely to spread this inflammatory signal (cells, nanovesi-
cles and soluble mediators) at the systemic level.33
‘Inflammaging’ is characterised by the presence of 
persistent low- grade inflammation that leads to deficient 
tissue repair and degeneration, and that increases plasma 
levels of inflammatory cytokines and acute- phase reac-
tants. Among the cytokines that have been involved in 
this process are: IL-6, IL-1β, TNF-α, IFN-γ and IL- 1RA.1 5 
The analysis of the immunosenescence profile in patients 
with SLE has shown an increase in IFN-γ levels that has 
been related to cardiovascular complications. Further-
more, an increase in the IL-6/transforming growth factor 
beta ratio has also been described in these patients with 
a consequent overexpression of IL-22 and IL-17. In addi-
tion, patients with RA develop features of accelerated 
ageing, including immunosenescence. These changes 
include decreased thymic functionality, expansion 
of late- differentiated effector T cells, increased telo-
meric attrition and excessive production of cytokines 
(senescence- associated secretory phenotype).34 There-
fore, it should be emphasised that a pattern of cytokine 
expression is observed in AID similar to that seen in 
‘inflammaging’ with similar consequences15 (figure 2).
The relationship between inflammation and vascular 
stiffness, the main clinical vascular ageing variable
In the clinic, vascular stiffness is the most commonly used 
measure to determine vascular age. It correlates well with 
chronological age, it is predictive for various major cardi-
ovascular endpoints, and it is affected by the most impor-
tant structural and functional vascular changes that occur 
during ageing.35–38 In the arterial wall, the low- grade pro- 
inflammatory milieu characteristic for the ageing process 
triggers morphological, microscopical and functional 
changes. The entire process of vascular ageing has been 
recognised as the ‘pro- inflammatory arterial stiffness 
syndrome’.35 The components of inflammaging have 
been shown to be associated with the development of this 
process.7 39 40
These alterations can not only develop with ageing, 
but also be induced in young animals under experi-
mental pro- inflammatory stimulation.41 When these 
molecular processes are taken into account, arterial 
stiffness is understood to be the most important deter-
minant for establishing vascular age, and that is bears 
relationship with inflammaging.7 42 Accordingly, the rele-
vant features of vascular ageing play a combined role in 
the outcome of stiffness measurements (ie, pulse wave 
velocity (PWV))36–38 (figure 3). If AID plays a role in 
vascular ageing induced by inflammation, vascular stiff-
ness should be correlated with AID.
In the next section, we explore this relationship with 
an extensive, non- systematic review that is focused on 
inflammaging, RA and PWV. PWV was chosen because it 
has been considered gold standard to assess arterial stiff-
ness, there is large epidemiological evidence of its predic-
tive value for cardiovascular events, and it correlates well 
with vascular age.7 RA has been analysed as a model for 
research mechanisms linking inflammation with cardio-
vascular risk and it is considered that studying pathways 
shared by both RA and atherosclerosis may provide 
insight into potential mechanisms of risk.29
NON-SYSTEMATIC REVIEW OF INFLAMMAGING, RA AND 
VASCULAR STIFFNESS
Method
An extensive non- systematic review of the literature was 
done with the Medical Subject Headings (MeSH) terms 
“vascular stiffness,” and the keywords “arterial stiffness,” 
“pulse wave velocity,” “PWV” and “inflammaging” that 
were crossed with the MeSH terms “rheumatoid arthritis” 
and “Arthritis, rheumatoid” in Pubmed up to 28 July 
2020 (see online supplemental table S1). Articles eval-
uating adult patients with RA and a comparison group 
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of subjects without RA and without any other AID were 
included (cross- sectional, cohort studies, and cases and 
controls). The main outcome was the measurement of the 
carotid–femoral PWV by applanation tonometry, oscillo-
metric method or Doppler ultrasound. Human studies 
were eligible if they met the following criteria: (1) full- 
length publications in peer- reviewed journals; (2) case–
control, cross- sectional or longitudinal, observational 
or analytical in design; (3) studies of adult patients with 
RA fulfilling validated criteria with a control group; (4) 
provided sufficient data on PWV measurement parame-
ters. No restriction criteria were imposed with regard to 
the type of the control healthy population studied. Over-
lapping populations were excluded (ie, same group of 
authors, same year, only one was considered). In addition, 
studies were excluded if they did not mention quantita-
tive assessment of the physiological confounders of PWV 
(ie, blood pressure, heart rate, correction for age or risk 
factors such as DM2). Narrative or systematic review, case 
report or series, studies not involving human study or 
studies contained other autoimmune populations were 
also excluded. No language or year filters were applied to 
carry out the search.
Statistical analysis was done with comprehensive 
meta- analysis Software. Data from the articles chosen 
were pooled using the random- effects model (DerSimo-
nian and Laird) due to the studies’ high heterogeneity 
(sample size, study design, primary objective) to estab-
lish an overall effect (mean difference with a CI and the 
respective p value). Studies evaluating PWV under the 
same measurement’s techniques were analysed. A meta- 
regression was done to analyse the influence of age and 
inflammatory activity on pooled PWV. Evidence level and 
methodological quality assessment was done by using the 
Joanna Briggs Institute checklists.
Results
The initial search yielded a total of 712 articles with the 
following terms and Boolean operators: “Arterial stiff-
ness” and “rheumatoid arthritis”, 206 articles; “Pulse 
wave velocity” AND “rheumatoid arthritis”, 154 articles; 
“PWV” AND “rheumatoid arthritis”, 73 articles; “Vascular 
stiffness” and “rheumatoid arthritis”, 170 articles. For 
the above searches, the same result was obtained when 
combined with the MeSH term “arthritis, rheumatoid.” 
For the search related to ‘inflammaging’ and ‘rheumatoid 
Figure 2 Shared mechanisms in healthy ageing and autoimmune systemic diseases leading to vascular ageing. In the case of 
autoimmune systemic diseases, inflammatory status (acute- phase reactants, cytokines and adhesion molecules upregulation) 
and vascular remodelling (high vascular stiffness) are a result of the breakdown self- tolerance due to the mentioned risk 
factors. While in older healthy adults these immunological and vascular changes are linked with immunosenescence, 
mitochondrial dysfunction, oxidative stress and DNA damage. *Secondary senescence. EC, endothelial cell; IFN-γ, interferon 
gamma; IL-1β, interleukin 1 beta; IL- 1RA, interleukin 1 receptor antagonist; IL-6, interleukin 6; SASP, senescence- associated 
secretory phenotype; SNCs: senescent cells; TNF-α, tumour necrosis factor alpha; VSMC, vascular smooth muscle cells.
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arthritis’, only 10 articles were found, all corresponding 
reviews of the literature were not related to RA.
In total, 20 articles met the inclusion criteria, they were 
evaluated, and the main outcome established. There 
were no overlapping populations. The global popula-
tion was 2417 subjects, of which 1104 corresponded to 
patients with RA and 1099 to subjects without RA. There 
were no age differences between cases and controls 
except for one study (see online supplemental table S2). 
Female sex was the most prevalent in both groups, 84.6% 
in cases and 77.8% in controls (see online supplemental 
table S2).
For the measurement of PWV, the applanation tonom-
etry method was the most frequently used in the study 
protocols. About 72% of the retrieved publications 
showed an increase in PWV with a statistically significant 
difference between patients with RA and the population 
without RA. Additionally, moderate- to- severe DAS-28 
(Composite Disease Activity Score) scores were found 
in 92.3% of the articles in which a significant increase 
in PWV values were found compared with controls (see 
online supplemental table S2). Twelve studies were 
included in the meta- analysis (those evaluating PWV 
through applanation tonometry). The pooled analysis 
under a random- effects model demonstrated a higher 
PWV in patients with RA (0.712; 95% CI 0.377 to 1.048; 
Χ2 p<0.000; I=2.82%) compared with controls (see online 
supplemental figure S1). Meta- regression models showed 
that age in cases and controls did not have an impact on 
the PWV difference between groups (coefficient=0.55; 
p=0.38 and coefficient=0.71; p=0.22, respectively). An 
additional meta- regression evaluating the DAS-28 impact 
on PWV difference showed that DAS-28 increase the PWV 
difference between groups (coefficient=0.69; p=0.038). 
Evidence level and methodological quality assessment 
was developed (see online supplemental table S3).
IMPLICATIONS OF THE PRESENT AND PREVIOUS REVIEWS
Through this extensive review of the literature, an increase 
in PWV in patients with RA was made evident compared 
with populations without RA and without other AID (see 
online supplemental table S2). In addition, it should be 
noted that there is a statistically significant relationship 
between inflammatory activity of the disease (measured 
through the DAS-28 index) and the increase in carotid–
femoral PWV. With PWV, the arterial stiffness increases, 
and thus the chronological vascular age calculated from 
it.37 43 Patients and controls had similar age, and this did 
not influence the PWV difference as shown through the 
meta- regression models. Although the primary studies 
did not calculate the vascular age, it could be inferred 
that the vascular age of the cases would be higher, since 
they have a higher PWV which, according to the age- 
adjusted reference curve for PWV, corresponds to a 
higher vascular age. Therefore, the results of this review 
of the literature should indicate that individuals with RA 
have accelerated vascular ageing compared with controls 
without RA and probably related to the chronic inflam-
matory state.
Figure 3 Inflammation and arterial stiffness. A pro- inflammatory milieu contributes to endothelial dysfunction and vascular 
remodelling. Arterial stiffness, as the main determinant of vascular age, can be measured by PWV or augmentation indexes. 
AIX@75, augmentation index adjusted to 75 beats per min; IFN-γ, interferon gamma; IL-1β, interleukin 1 beta, IL- 1RA, 
interleukin 1 receptor antagonist; IL-6, interleukin 6; IL-10, interleukin 10; MMP, metalloproteinases; PWV, pulse wave velocity; 
TIMPs, metalloproteinases inhibitors; TNF-α, tumour necrosis factor alpha.
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In a meta- analysis carried out by Ambrosino et al in 2015, 
an increase in the greater aortic and brachial PWV as well 
as in the rate of aortic augmentation adjusted to 75 beats 
per min was demonstrated when they compared patients 
with RA with healthy subjects.44 The present study rein-
forces the findings of Ambrosino et al and updates the 
search carried out by them, including 10 new studies.
Biomarkers that link AID with vascular stiffness
Södergren et al studied biomarkers associated with early 
RA (diagnosed in the previous 12 months) and CVD. 
They found a difference between the levels of the mono-
cyte migration inhibitory factor, a biomarker associated 
with atherosclerosis, in patients compared with controls.45 
However, adjusting this for sex and age of the patients 
was not correlated with carotid intima–media thickness 
(cIMT) values. In contrast, Lo Gullo et al demonstrated 
a direct relationship between higher levels of IL-1β and 
the expression of CRP, reactive oxygen species, and a 
higher PWV value. Furthermore, Marder et al have shown 
a significant positive association between IL-17 levels 
and PWV values. Bazzichi et al found that patients with 
AID (RA and scleroderma) had higher levels of PWV 
compared with healthy individuals, and that this increase 
was related to osteopontin levels, specifically in individ-
uals with RA. These levels are a predictor of an increase 
in PWV after an analysis adjusted for confounding varia-
bles.46–48
Recently, it has been suggested that the way the process 
of arterial remodelling, both in its arteriosclerotic 
component and in endothelial dysfunction, is activated 
by extracellular matrix metalloproteinases (MMPs) indi-
cates that its inhibition could slow down the vascular 
pro- inflammation associated with age.35 49 50 Among the 
molecular patterns known as molecular phenotypes 
of the ageing arterial wall, the MMP phenotype stands 
out as one of the most important in this process. This 
highlights the special participation of MMP 1, 2 and 9 
with a fundamental role in vascular ageing process as 
well as the antagonistic role of tissue MMP inhibitors 
(TIMPs).35 51 52 In addition, MMP expression and its 
activity usually correlate with severity in both AID (ie, 
psoriasis, SLE, RA and so on) and disorders of infectious 
origins. In fact, the imbalance of pro- inflammatory and 
anti- inflammatory cytokines seen in pathology of RA may 
result in part from altered balances in the MMP/TIMP 
proteolytic axis. Furthermore, in this disease, angiogen-
esis also occurs at the site of inflammation and it has been 
shown that MMPs regulate the bioavailability of several 
angiogenic factors such as vascular endothelial growth 
factor, fibroblast growth factor receptor and epithelial 
growth factor.52
Thus, in individuals with hypertension, an increase in 
PWV has been shown to be in parallel with an increase 
in MMP 2 and MMP 9 when compared with individuals 
without hypertension.53 In other studies of individuals 
with hypertension under an antihypertensive therapeutic 
regimen, a decrease in arterial stiffness has been shown 
associated with a decrease in MMP and an increase in 
TIMP-1.54
Taking all of the above into account, a myriad of pro- 
inflammatory cytokines and MMPs have been identified 
as potential effectors of accelerated vascular ageing asso-
ciated with AID. Therefore, this field of study is likely to 
be a viable way to result in clinical application.
Therapeutic targets and horizons in the treatment of CVD in 
patients with RA
CVD risk assessment in RA
An important approach to reduce cardiovascular risk in 
patients with RA is the tuning between specific risk assess-
ment and AID pharmacotherapy. In clinical practice, 
some guidelines suggest performing a cardiovascular risk 
assessment on patients with RA at least every 5 years using 
tools, for example the Framingham score, that make it 
possible to predict cardiovascular risk and establish a 
management plan, as is done in the general population. 
Note that the Framingham score must be multiplied by 
1.5 for patients with RA to obtain the final result. Alterna-
tively, one can use scales specific for this population, such 
as the Systematic Coronary Risk Evaluation (SCORE), 
the Expanded Cardiovascular Risk Prediction Scale score 
for RA and the QRISK2 scale.55 However, although there 
is biological plausibility for the use of this adjustment 
or these scales, there is still no clear validation for these 
generalised recommendations, and cardiovascular risk 
calculations for patients with RA should rather be done 
individually and with great caution.20 56 57 In the European 
consensus for the control of cardiovascular risk in RA 
and inflammatory arthropathies, emphasis is placed on 
disease control to decrease cardiovascular risk.55 There-
fore, the effect of pharmacotherapy should become an 
integral part of the risk assessment. This includes effects 
of both AID as well as cardiovascular drugs.
Current pharmacotherapy in patients with RA and its effect on CVD
The use of statins in patients with RA with primary CVD 
risk prevention has been shown to reduce arterial stiff-
ness and carotid plaque formation regardless of the 
reduction in LDLs. Furthermore, in patients with RA 
who discontinued statin therapy, it was found that at 3 
months, the risk of myocardial infarction had increased 
by 67%, and that it increased an additional 2% for each 
month after that.57 Its discontinuation is also related to a 
60% increase in the risk of cardiovascular mortality and 
79% of all- cause mortality in patients with RA.58 Hence, 
the use of statins in patients with RA is strongly indicated 
according to national lipid guidelines considering the 
SCORE CVD risk prediction model if no national guide-
line is available to stratify the CVD risk in these patients 
to take the decision.55
The use of statins also modulates non- CVD processes. A 
study evaluating patients with RA being treated with at least 
one disease- modifying antirheumatic drug (DMARD) 
showed that concomitant use of statins reduced all- cause 
mortality by 21%.57 In patients with RA in which statin 
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is added to the regimen of methotrexate and cortico-
steroids, the disease activity declines significantly, which 
could suggest a direct role in disease control.57 58 Indeed, 
beyond the LDL- lowering action, statins are known to 
exert anti- inflammatory and immune- modulating effects 
by inhibiting MMPs, nuclear factor kappa beta (NF-ĸβ), 
cell adhesion and migration molecules such as selectins 
and vascular cell adhesion molecule 1. These effects of 
statins, which have been comprehensively reviewed else-
where,59 might account for the additive effect on AID 
drugs.
In contrast, the use of glucocorticoids might increase 
CVD. Although it is true that glucocorticoids are part 
of the treatment of patients with AID, and that eventu-
ally, in particular cases, non- steroidal anti- inflammatory 
drugs are used, it is pertinent to closely monitor the ther-
apeutic management since this medication adds greater 
cardiovascular risk to the underlying disease.60 In partic-
ular, sustained glucocorticoid treatment increases risk 
for CVD through multiple pathways. Although gluco-
corticoid therapy might promote hypertension, its risk- 
increasing effect is best explained not by hypertension 
alone, but rather by the metabolic effects of prolonged 
glucocorticoid treatment on other pathways, particularly 
impaired glucose tolerance, including overt diabetes and 
disturbances in serum lipids.61 In fact, disturbances in 
plasma cortisol levels predispose to the development of 
a variety of pathologies with atherosclerotic CVD being 
a top killer in patients suffering from primary adrenal 
insufficiency or Cushing’s syndrome/disease.62
Next to glucocorticoids, conventional DMARDs have 
been used in clinical practice for a long time, and there 
is information available regarding their cardiovascular 
profile. With respect to methotrexate, the most widely 
used synthetic conventional DMARD, there are meta- 
analyses that show that its use reduces cardiovascular 
risk by between 21% and 28%. Similarly, the use of 
hydroxychloroquine and sulfasalazine as well as their 
combinations has also been associated with a decrease 
in cardiovascular risk.60 63 Thus, next to statins the use 
of such DMARDs is indicated in all patients with RA 
according to the disease activity level in order to control 
the disease and the consequences of chronic inflamma-
tion at the cardiovascular level.55
The use of biological DMARDs (ie, monoclonal anti-
bodies, fusion proteins, TNF inhibitors and non- TNF 
inhibitors) is significantly associated with the regulation 
of the chronic inflammatory process and thus, they could 
be considered potential therapeutic drugs with a direct 
effect on the ‘inflammaging’ which would reduce the 
risk of CVD. Table 1 lists studies that evaluated impact of 
biological DMARDs on cardiovascular risk and function. 
In particular, the decrease in PWV in patients with RA 
under treatment with biological DMARDS illustrates the 
anti- ageing effect in the vasculature. The impact of the 
introduction of biological medicines in RA has been such 
that by 2010, in some cohorts, CVD mortality rates in 
this population decreased progressively and significantly 
until they reached levels close to that of the general 
population. This could be due in part to the use of this 
type of DMARDs.64 65 In fact, a meta- analysis suggested 
that anti- TNF treatment may have a beneficial effect on 
aortic stiffness and, therefore, on cardiovascular risk.66 It 
is appealing to hypothesise that cardiovascular improve-
ment the use of these DMARDs entails is a result of an 
effect on inflammaging, as can be expected for TNF 
inhibition.65 Specific in- depth study of this possibility will 
be needed to confirm this and to provide a rationale for 
the targeted use of such drugs to decrease CVD risk in 
patients with AID.
The effects of both biological and conventional 
DMARDs have been also studied on measures of subclin-
ical atherosclerosis and vascular dysfunction (hence, 
vascular ageing) besides PWV. The impact of methro-
texate, sulfasalazine and hydroxychloroquine on cIMT, 
and flow- mediated dilation (FMD), surrogate markers of 
atherosclerosis and endothelial dysfunction, respectively, 
has been tested.67 After a year of treatment, a significant 
decrease in cIMT and an improvement in FMD have been 
found. Additional research has shown similar results.68 69
Regarding biological DMARDs, its beneficial effect 
has been described on endothelial function and subclin-
ical atherosclerosis in patients with RA. Adalimumab 
was associated with improvement in FMD without cIMT 
progression, after 12 months of treatment in patients with 
refractory RA to conventional treatment.70 In another 
study, anti- TNF therapy was associated with a reduction 
in cIMT progression.71
Similar effects have been observed under treatment 
with other biologics besides anti- TNF agents (table 1). 
In a study that for the first time evaluated the effect of 
rituximab on endothelial dysfunction, it has shown 
a dramatic improvement of FMD at 6 months of treat-
ment.71 However, the research of the potential beneficial 
effect on CVD (measured through FMD and cIMT) of 
this and other biological therapies is still needed.
On the other hand, the coronary artery calcium score 
(CACS), performed by coronary CT angiography, is a 
strong predictor of cardiovascular events and is poten-
tially useful for improving the cardiovascular risk assess-
ment in asymptomatic people. A higher prevalence of 
coronary artery calcification has been found in patients 
with RA,71 but research is still needed to establish the roll 
of treatment on CACS.
Novel biological drugs make it possible to find addi-
tional therapeutic options with adequate efficacy and 
safety. One possibility is blockade of the complement 
pathways. Apart from the possible benefits of eculizumab, 
inhibitor of C5 cleavage, in AID, its use is being consid-
ered as a possible therapy for membranous glomerulop-
athy.72 Another strategy involves metabolic adaptation of 
immune cells. Given their energy and substrate require-
ments for differentiation and activation, unravelling the 
relation of metabolism and immune cell function is now 
an active field of investigation and will allow the devel-
opment of therapeutic strategies such as the modulation 
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of pro- inflammatory metabolism.73 Recently, metabolism- 
modulating therapies are under study in patients with 
AID. For example, effects of metabolic regulators of mito-
chondrial function and biogenesis such as metformin 
(by means of mitochondrial complex I inhibition) are 
explored in RA and SLE. Agents that inhibit mammalian 
target of rapamycin (ie, sirolimus, rapamycin and temsi-
rolius), a main metabolic switch that is unusually active in 
many autoinflammatory and AID, are under investigation 
as well in RA, SLE, DM2 and multiple sclerosis. Further-
more, effects of some activators of SIRT 1, an important 
nutrient- sensing protein that suppresses NF-κβ-depen-
dent inflammatory responses, (eg, resveratrol) are under 
evaluation in patients with RA.74 75 In addition, new 
therapeutic targets in the inflammatory signalling path-
ways are under study, and others are considered poten-
tial candidates for AID, particularly RA and SLE. Some 
of these pathways concern extracellular targets such as 
macrophage granulocyte colony- stimulating factor inhib-
itors (eg, mavrilimumab) and other intracellular binding 
sites such as new inhibitors of the JAK pathway (eg, filgo-
tinib), inhibitors of the Bruton’s tyrosine kinase pathway 
or phosphoinositol 3- kinase, or new targets at the level 
of dendritic cells or the Fc- gamma receptor.75 76 Again, 
the facts summarised here highlight the potential role of 
‘inflammaging’ pathways with the development of arte-
rial stiffness and endothelial dysfunction in patients with 
AID.
CONCLUSIONS
Pathologies characterised by a continuous state of imbal-
ance between the production of pro- inflammatory and 
anti- inflammatory molecules, which is what occurs in AID 
(eg, RA), lead to an accelerated process of arterioscle-
rosis, vascular remodelling and, therefore, an increased 
vascular age, resulting in an increase in the morbidity 
and mortality rate from cardiovascular events.
Inflammaging and its vascular impact in the context of 
AIDs such as RA open a new field of medical research. 
This discipline is marked by early, personalised diag-
nosis and risk stratification, through the combination 
of routinely used non- invasive vascular function tests as 
well as AID variables. It offers opportunities for novel 
approaches in the field of clinical pharmacology and 
personalised medicine, in which specific combinations 
of statins with immune- modulating AID drugs play a 
leading role, and may benefit both CVD as well as AID 
progression. Thus, inflammaging has become a target 
for primary and secondary prevention of cardiovascular 
events in patients with a pathology that is immunological 
in origin.
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